A local genetic screening company has secured a national contract with the third-largest health insurer in the country.
Grand Rapids-based NxGen MDx said yesterday its genetic screening and pre-natal testing will be available on an in-network basis for Aetna’s 46-million members, beginning Feb. 15.
"Like NxGen MDx, Aetna's goal is to provide tools to help physicians and patients make informed decisions about their health care. We are both trying to accomplish the same goal," said Alan Mack, CEO, NxGen MDx.
Aetna’s millions of members will have in-network access to genetic testing for up to 120 genetic disorders through panels and stand-alone screens.
NxGen MDxCFO Kristin Sherman said the agreement “removes a barrier” for health care professionals who have wanted access to the company’s product offerings.
The company said the deal was supported by “many physicians” in theAetnanetwork, due to a belief in its product suite.